ArticleFrontiers in oncology2025
Unilateral sudden hearing loss as the first presenting symptom of chronic myeloid leukemia: a case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic myeloid leukemia (CML) with sudden deafness as the first symptom is clinically rare and easily overlooked. No conventional treatment for CML-associated sudden hearing loss exists and hearing outcomes remain poor. Here, we describe a case in which sudden unilateral hearing loss was the first presenting symptom in a patient ultimately diagnosed with CML. The patient received imatinib mesylate, sodium bicarbonate, and allopurinol for CML, and systemic and local steroids, hemoreological therapy, and nutritional neurological drugs for hearing loss. Although the patient's CML was effectively controlled, his hearing could not be restored. In the second part of the manuscript, we present the results of a systematic review of case reports of CML-associated sudden hearing loss, identified by screening PubMed, Web of Science, and Medline. Seventeen patients were identified. Hyperviscosity syndrome and labyrinthine artery occlusive infarction were the most common pathogenic mechanisms of hearing loss. In terms of auditory outcomes, eight patients showed no improvement, while nine demonstrated positive outcomes. Among those with improved hearing, four had undergone cochlear implantation, one received intrathecal methotrexate, and one underwent leukoreduction therapy. Aggressive cochlear implantation could improve hearing outcomes in cases where cochlear ossification has not taken place and the leukemia is controlled.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.